Breakthrough Eye Implant and Advanced Glasses Give Hope to Legally Blind Individuals

According to recent research, tiny microchips inserted at the rear of the eyes in some legally blind individuals have allowed a number of them to regain their ability to read.

In a study involving 32 participants with a severe type of dry macular degeneration, known as geographic atrophy, 26 exhibited 'significant gains in visual acuity' within a year following the implant procedure.

The innovative process involves placing a slender implant beneath the retina—thinner than a strand of hair. Patients are then required to wear specialized glasses equipped with a camera that sends images to the implant using near-infrared light. This system, consisting of the glasses and implant, is termed the photovoltaic retina implant microarray (PRIMA).

Sheila Irvine, age 70, experienced this treatment and described her renewed ability to read and complete crossword puzzles as 'incredible,' expressing gratitude for participating in cutting-edge technology.

Despite her considerable progress, using the PRIMA glasses demands significant focus. To stabilize the camera, she utilizes a pillow to support her chin, and she can only view a few letters simultaneously. Letters such as C and O can be difficult to differentiate without activating the magnification setting.

Geographic atrophy, afflicting approximately 5 million individuals globally, is a primary cause of blindness among the elderly. Previously, there were no solutions to enhance reading or facial recognition abilities, remarked study lead author Frank Holz.

Holz, a retina specialist from Germany, pointed out that prior methods were pharmacological, aiming to decelerate the spread of retinal damage.

In 2023, the U.S. Food and Drug Administration sanctioned the use of the first drug designed to address geographic atrophy, administered via injection to help slow its advance, though it doesn't restore vision.

Macular degeneration exists in two variations: wet and dry. The wet type leads to abnormal blood vessel formation under the retina, causing scarring. This affects 15% of sufferers and has had treatment options available.

Conversely, the dry form, more prevalent, leads to a thinning macula with protein deposits called drusen forming. With the FDA's recent approval of Syfovre, some hope for treatment now exists.

Thanks to the 2-by-2-millimeter implant, visual precision can be revived in patients whose central vision had been completely lost, maintained researcher Holz.

Dr. Jon LaPook from CBS News indicated that despite the promising nature of this device for geographic atrophy patients, the study was limited in scale.

Developed by Science Corporation, the PRIMA implant is not yet commercially available and remains within clinical trials, reported the BBC.

Max Hodak, CEO of Science, expressed excitement about PRIMA's potential to revolutionize vision recovery, emphasizing the company's mission to innovate technologies that can profoundly impact patients' lives.